bingo, proves my point there really isn’t a long list. FTO and m6A as a biomarker that is relevant to all cancers.
realistically if the all comers trial covers 10-15 cancers it would be akin to running this number of trials. So when we do get the results the data will be very compelling to Pharma. That’s before we get the official word on cardioprotection translating across multiple classes of cardiotoxic drugs.
@johndprent the ATH was reached with ovarian preclinicals and AML Sheba 1. Even if it was FOMO there has been a lot of progress with RC220 and CPACS.
Right now the market is making every biotech earn each cent, and so it should. But as you can see from a few standouts it pays handsomely when things work out.
DYOR
Intellectual Property (IP) Waterproofing., page-28
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.46 |
Change
0.000(0.00%) |
Mkt cap ! $248.7M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 21333 | $1.50 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.50 | 304 | 1 |
View Market Depth
| Last trade - 07.20am 21/08/2024 (20 minute delay) ? |
| RAC (ASX) Chart |
Day chart unavailable